TrialBlood2012

A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.

Geoffrey L Uy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.